Biogen’s Profit Forecast Tops Estimates on Cost-Cutting

Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.

Adjusted earnings will be between $15.25 and $16.25 a share this year, the Cambridge, Massachusetts-based biotech said in a statement Friday, topping the average of analyst estimates. Revenue is projected to fall by a mid-single-digit percentage, extending pressure on a business long reliant on MS treatments.